Till startsida
To content Read more about how we use cookies on gu.se


2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 
(only publications since 2007, in total over 500 publications)


Hoffmann JM, Grünberg JR, Church C, Elias I, Palsdottir V, Jansson J-O, Bosch F, Hammarstedt A, Hedjazifar S and Smith U: BMP4 gene therapy in mature mice reduces BAT activation but protects from obesity by browning subcutaneous adipose tissue. Cell Rep 20:1038-1049, 2017.

Mardinoglu A, Stancáková A, Lotta LA, Kuusisto J, Borén J, Blüher M, Langenberg C, Ferrannini E, Groop PH, Laakso M, Wareham NJ and Smith U: Plasma mannose levels are associated with incident type 2 diabetes and cardiovascular disease. Cell Metab 26:281-283, 2017.

Lee S, Zhang C, Liu Z, Klevstig M, Mukhopadhyay B, Bergentall M, Cinar R, Ståhlman M, Sikanic N, Park JK, Deshmukh S, Harzandi AM, Kuijpers T, Grøtli M, Elsässer SJ, Piening BD, Snyder M, Smith U, Nielsen J, Bäckhed F, Kunos G, Uhlen M, Boren J and Mardinoglu A: Network analysis identify liver-specific targets for treating liver diseases. Mol Syst Biol 13:938-952, 2017.

Ohlsson C, Hammarstedt A, Vandenput L, Saarinen-Aaltonen N, Ryberg H, Windahl S, Farman H, Jansson J-O, Movérare-Skrtic S, Smith U, Zhang F-P, Poutanen M, Hedjazifar S and Sjögren K: Increased adipose tissue aromatase activity improves insulin sensitivity and reduces adipose tissue inflammation in male mice. Am J Physiol Endocrinol Metab doi:10.1152/ajpendo.00093.2017.

Westwood S, Liu B, Baird AL, Anand S, Nevado-Holgado AJ, Newby D, Pikkarainen M, Hallikainen M, Kuusisto J, Streffer JR, Novak G, Blennow K, Andreasson U, Zetterberg H, Smith U, Laakso M, Soininen H and Lovestone S: The influence of insulin resistance on cerebrospinal fluid and plasma biomarkers of Alzheimer’s pathology. Alzheimers Res Ther 9(1):31, 2017.

Wood AR, Jonsson A, Jackson A, ..., Smith U, ..., Hanson RL and Frayling TM: A genome-wide association study of IVGTT-based measures of first phase insulin secretion refines the underlying physiology of type 2 diabetes variants. Diabetes doi: 10.2337/db16-1452, 2017.

Grünberg JR, Hoffmann JM, Hedjazifar S, Nerstedt A, Jenndahl L, Elvin J, Castellot J, Wei L, Movérare-Skrtic S, Ohlsson C, Mannerås Holm L, Bäckhed F, Syed I, Bosch F, Saghatelian A, Kahn BB, Hammarstedt A and Smith U: Overexpressing the novel autocrine/endocrine adipokine WISP2 induces hyperplasia of the heart, white and brown adipose tissues and prevents insulin resistance. Sci Rep 7:43515, 2017.

Mardinoglu A, Bjornson E, Zhang C, Klevstig M, Söderlund S, Ståhlman M, Adiels M, Hakkarainen A, Lundbom N, Kilicarslan M, Hallström BM, Lundbom J, Vergès B, Barrett PHR, Watts GF, Serlie M, Nielsen J, Uhlén M, Smith U, Marschall H-U, Taskinen M-R and Boren J: Personalized genome-scale modeling identifies NAD and glutathione metabolism as a target for treatment of NAFLD. Mol Syst Biol 13:916, 2017.

Eliasson B, Rawshani A, Axelsen M, Hammarstedt A and Smith U: Cephalic phase of insulin secretion in response to a meal is unrelated to family history of Type 2 diabetes. PLoS ONE 12:e0173654, 2017.


Smith U and Kahn BB: Adipose tissue regulates insulin sensitivity: role of adipogenesis, de novo lipogenesis and novel lipids. J Intern Med 280:465-475, 2016.

Walford G.A, Gustafsson S, Rybin D, ..., Smith U, ..., Ingelsson E and Florez J.C: Genome-wide association study of the modified Stumwoll Insulin Sensitivity Index identifies BCL2 and FAM19A2 as novel insulin sensitivity loci. Diabetes 65:3200-3211, 2016.

Van Raalte DH, Bunck MC, Smits MM, Hoekstra T, Cornér A, Diamant M, Eliasson B, Taskinen M-R, Heine RJ, Smith U, Yki-Järvinen H and Mari A: Exenatide improves beta-cell function up to 3 years of treatment in patients with Type 2 diabetes: a randomized controlled trial. Eur J Endocrinol 175:345-352, 2016.

Lee S, Zhang C, Kilicarslan M, Piening BD, Bjornson E, Hallström BM, Groen AK, Ferrannini E, Laakso M, Snyder M, Blüher M, Uhlen M, Nielsen J, Smith U, Serlie M, Borén J and Mardinoglu A. Integrated network analysis reveals an association between plasma mannose levels and insulin resistance. Cell Metab 24:172-184, 2016.

Lewerin C, Johansson H, Karlsson MK, Lorentzon M, Lerner UH, Kindblom JM, Ohlsson C, Smith U and Mellström D: High plasma osteocalcin is associated with low blood haemoglobin in elderly men: The MrOS Sweden study. J Intern Med 280:398-406, 2016.

Mardinoglu A, Borén J and Smith U: Confounding effects of metformin on the human gut microbiome in Type 2 diabetes. Cell Metab 23:10-12, 2016.

Smith U: Is leptin coming back? Diabetologia 59(5):918-919, 2016.

Zhang T, Chen S, Syed I, Ståhlman M, Kolar MJ, Homan EA, Chu Q, Smith U, Borén J, Kahn BB and Saghatelian A. A LC-MS-based workflow for measurement of branched fatty acid esters of hydroxy fatty acids. Nature Protocols 11 (4):747-763, 2016.

Smits M, Bunck M, Diamant M, Corner A, Eliasson B, Heine R, Smith U, Yki-Järvinen H and van Raalte D: Effect of 3-years treatment with exanatide on postprandial glucagon levels. Diab Care 39:e42-3, 2016.


Amrutkar M, Cansby E, Chursa U, Nunez-Durán E, Chanclón B, Ståhlman M, Fridén V, Mannerås-Holm L, Wickman A, Smith U, Bäckhed F, Borén J, Howell B.W and Mahlapuu M: Genetic disruption of protein kinase STK25 ameliorates metabolic defects in a diet-induced Type 2 Diabetes model. Diabetes 64:2791-2804, 2015.

Gustafson B and Smith U: Regulation of white adipogenesis and its relation to ectopic fat accumulation and cardiovascular risk. Atherosclerosis 241:27-35, 2015.

Amrutkar M, Cansby E, Nunez-Duran E, Pirazzi C, Stahlman M, Stenfeldt E, Smith U, Boren J, Mahlapuu M. Protein kinase STK25 regulates hepatic lipid partitioning and progression of liver steatosis and NASH. FASEB J 29:1564-76, 2015.

Smith U: Abdominal obesity – a marker of ectopic fat accumulation. J Clin Invest 125(5):1790-1792, 2015.

Lewerin C, Johansson H, Lerner U.H, Karlsson M.K, Lorentzon M, Barrett-Connor E, Smith U, Ohlsson C and Mellström D: High serum adiponectin associates with low blood hemoglobin in elderly men; The MrOS Sweden study. J Int Med 278:68-76, 2015.

Gustafson B, Hedjazifar S, Gogg S, Hammarstedt A and Smith U: Insulin resistance and impaired adipogenesis. Trends Endocrinol Metab 26:193-200, 2015.

Gustafson B, Hammarstedt A, Hedjazifar S, Hoffman J.M, Svensson P-A, Grimsby J, Rondinone C and Smith U: BMP4 and BMP antagonists regulate human white and beige adipogenesis. Diabetes 64:1670-1681, 2015.

Cederberg H, Laakso M and Smith U: Family history of Type 2 diabetes increases risk of obesity and metabolic complications – is Type 2 diabetes a disease of inappropriate lipid storage? J Int Med 277:540-551, 2015.


Cansby E, Nerstedt A, Amrutkar M, Nuñes Durán EN, Smith U and Mahlapuu M: Partial hepatic resistance to IL-6-induced inflammation develops in type 2 diabetic mice, while the anti-inflammatory effect of AMPK is maintained. Mol Cell Endocrinol 393:143-151, 2014.

Yore M.M, Syed I.S, Moraes-Vieira P.M, Zhang T, Herman M.A, Homan E.A, Patel R.T, Lee J, Chen S, Peroni O.D, Dhaneshwar A.S, Hammarstedt A, Smith U, McGraw T.E, Saghatelian A and Kahn B.B: Discovery of a Class of Endogenous Mammalian Lipids with Anti-Diabetic and Anti-inflammatory Effects. Cell 159(2):318-332, 2014.

Henninger AM, Eliasson B, Jenndahl LE and Hammarstedt A. Adipocyte hypertrophy, inflammation and fibrosis characterize subcutaneous adipose tissue of healthy, non-obese subjects predisposed to type 2 diabetes. PLoS One 9(8):e105262, 2014
Lovestone S and Smith U: Advanced glycation end products, dementia and diabetes: Proc Natl Acad Sci 111(13):4743-4744, 2014

Grünberg J.R, Hammarstedt A, Hedjazifar S and Smith U: The Novel Secreted Adipokine WNT1-Inducible-Signaling Pathway Protein2/Wisp2 is a Mesenchymal Cell Activator of Canonical Wnt. J Biol Chem 289:6899-6907, 2014

Van Raalte D.H, van Genugten R.E, Eliasson B, Möller-Goede D.L, Mari A, Tura A, Wilson C, Fleck P, Taskinen M-R, Smith U and Diamant M: The effect of aloglipitin and pioglitazone combination therapy on various aspects of beta-cell function in patients with recent-onset type 2 diabetes. Eur J Endocrinol 170:565-574, 2014

Eliasson B, Smith U, Mullen S, Cushman S.W, Sherman A.S and Yang J: Amelioration of insulin resistance by rosiglitazone is associated with increased adipose cell size in obese type 2 diabetic patients. Adipocyte 3(4):405-412, 2014

Dimas AS, Lagou V, Barker A, ..., Smith U, ..., Prokopenko I; on behalf of the MAGIC investigators: Impact of type 2 diabetes susceptibility variants on quantitative glycemic traits reveals mechanistic heterogeneity. Diabetes 63:2158-2171, 2014


Gustafson B, Hammarstedt A, Hedjazifar S and Smith U: Restricted Adipogenesis in Hypertrophic Obesity – role of WISP2, WNT and BMP4. Diabetes 62:2997-3004, 2013

Cansby E, Amrutkar M, Mannerås Holm L, Nerstedt A, Reyahi A, Stenfeldt E, Borén J, Carlsson P, Smith U, Zierath J.R, and Mahlapuu M: Increased expression of STK25 leads to impaired glucose utilization and insulin sensitivity in mice challenged with a high-fat diet. FASEB J. 27:3660-3671, 2013

Cederberg H, Gylling H, Miettinen T.A, Paananen J, Vangipurapu J, Pihlajamäki J, Kuulasmaa T, Stancaková A, Smith U, Kuusisto J and Laakso M: Non-cholesterol Sterol Levels Predict Hyperglycemia and Conversion to Type 2 Diabetes in Finnish Men. PLoS ONE 8:e67406, 2013

Nerstedt A, Cansby E, Amrutkar M, Smith U and Mahlapuu M: Pharmacological activation of AMPK suppresses inflammatory response evoked by IL-6 signalling in mouse liver and in human hepatocytes. Mol Cell Endocrinol 375:68-78, 2013

Hammarstedt A, Hedjazifar S, Jenndahl L, Gogg S, Grünberg J, Gustafson B, Klimcakova E, Stich V, Langin D, Laakso M and Smith U: WISP2 Regulates Preadipocyte Commitment and PPARgamma Activation by BMP4. Proc Natl Acad Sci 110:2563-2568, 2013

Halban P.A, Boulton A.J.M and Smith U: A new paradigm for improved coordination and efficacy of European biomedical research: taking diabetes as a model. Diabetologia 56(3):439-443, 2013

Xie W, Wood A.R, Lyssenko V, Weedon M.N, Knowles J.W, Alkayyali S, Assimes T.L, Quertermous T, Abbasi F, Paananen J, Häring H, Hansen T, Pedersen O, Smith U, Laakso M, MAGIC investigators, the DIAGRAM consortium, the GENESIS consortium, the RISC consortium, Dekker J.M, Nolan J.J, Groop L, Ferrannini E, Adam K-P, Gall W.E, Frayling T.M and Walker M: Genetic variants associated with glycine metabolism and their role in insulin sensitivity and type 2 diabetes. Diabetes 62:2141-2150, 2013

Yaghootkar H et al. Mendelian Randomization Studies Do Not Support a Causal Role for Reduced Circulating Adiponectin Levels in Insulin Resistance and Type 2 Diabetes. Diabetes 62:3589-3598, 2013

Schuetz C A, Alperin P, Guda S, van Herick A, Cariou B, Eddy D, Gumprecht J, Nicolucci A, Schwarz P E, Wareham N J, Witte D R, Smith U: A standardized vascular disease health check in Europe: a cost-effectiveness analysis. PLoS ONE 8(7):e66454, 2013


D’Esposito V, Passaretti F, Hammarstedt A, Liguoro D, Molea G, Canta P, Smith U, Beguinot F and Formisano P: Adipocyte-released insulin like growth factor-1 is regulated by glucose and fatty acids and controls breast cancer cell growth in vitro. Diabetologia 55(10):2811-2822, 2012

Smith U: PTEN - Linking Metabolism, Cell Growth, and Cancer. N Engl J Med 367:1061-1063, 2012

Hammarstedt A, Graham TE, Kahn BB: Adipose tissue dysregulation and reduced insulin sensitivity in non-obese individuals with enlarged abdominal adipose cells. Diabetol Metab Syndr 4(1):42, 2012

Pereira MJ, Palming J, Rizell M, Aureliano M, Carvalho E, Svensson MK and Eriksson JW. mTOR inhibition with rapamycin causes impaired insulin signalling and glucose uptake in human subcutaneous and omental adipocytes. Mol Cell Endocrinol 355(1):96-105, 2012

Gustafson B & Smith U: The Wnt inhibitor Dickkopf-Related Protein 1 and Bone Morphogenetic Protein 4 rescue adipogenesis in hypertrophic obesity in man. Diabetes 61:1217-1224, 2012

Yang J, Eliasson B, Smith U, Cushman S.W, Sherman A: The size of large adipose cells is a predictor of insulin resistance in first-degree relatives of type 2 diabetic patients. Obesity 20(5):932-938, 2012

Eliasson B, Moller-Goede D, Eeg-Olofsson K, Wilson C, Cederholm J, Fleck P, Diamant M, Taskinen M-R and Smith U: Lowering of postprandial lipids in subjects with type 2 diabetes treated with alogliptin and/or pioglitazone: a randomized, double blind, placebo-controlled study. Diabetologia 55:915, 2012

Smith U: The many facets of the HbA1c test. J Int Med 271:237-328, 2012

Norseen J, Hosooka T, Hammarstedt A, Yore M.M, Kant S, Aryal P, Kiernan U.A, Phillips D, Maruyama H, Kraus B.J, Usheva A, Davis R.J, Smith U and Kahn B.B: Retinol-Binding Protein 4 Inhibits Insulin Signaling in Adipocytes by Inducing Proinflammatory Cytokines in Macrophages through a c-Jun N-Terminal Kinase and Toll-Like Receptor 4-Dependent and Retinol-Independent Mechanism. Mol Cell Biol 32:2010, 2012

Nerstedt A, Cansby E, Andersson CX, Laakso M, Stancakova A, Blüher M, Smith U and Mahlapuu M: Stk25 – a novel negative regulator of lipid and glucose metabolism in skeletal muscle. Diabetologia 55:1797, 2012

Johansson H, Odén A, Lerner U H, Jutberger H, Lorentzon M, Barret Connor E, Karlsson M K, Ljungren Ö, Smith U, McCloskey E, Kanis J A, Ohlsson C and Mellström D: High serum adiponectin predicts incident fractures in elderly men: Osteoporotic fractures in men (Mr OS) Sweden. J Bone Miner Res 27:1390, 2012


Boström E.A, Svensson M, Andersson S, Jonsson I.M, Ekwall A.K, Eisler T, Dahlberg L.E, Smith U and Bokarewa M.I: Resistin and insulin/insulin-like growth factor signaling in rheumatoid arthritis. Arthritis Rheum 63(10):2894-2904, 2011.

Bunck M, Corner A, Eliasson B, Heine R, Shaginian R, Taskinen M-R, Smith U, Yki-Järvinen H and Diamant M. Effects of exenatide on measures of beta cell function after three years in metformin-treated patients with type 2 diabetes. Diabetes Care 34:2041-2047, 2011. 

Arner P, Arner E, Hammarstedt A and Smith U: Genetic predisposition for Type 2 diabetes, but not for overweight/obesity, is associated with a restricted adipogenesis. PLoS ONE 6(4): e18284, 2011

Wallerstedt E, Sandqvist M, Smith U and Andersson CX: Anti-inflammatory effect of insulin in the human hepatoma cell line HEPG2 involves decreased transcription of IL-6 target genes and nuclear exclusion of FOX01. Mol Cell Biochem 352:47-55, 2011

Mirza M AI, Alsiö J, Hammarstedt A, Lanske B, Erben R G, Windisch W, Michaelsson K, Jonsson K B, Marsell R, Tivesten Å, Orwoll E, Karlsson M K, Ljunggren Ö, Lind L, Mellström D, Ohlsson C, Larsson T E:
Circulating FGF23 reveals a novel role in regulation of fat mass and associates with obesity-related phenotypes in human.
Arterioscler Thromb Vasc Biol 31(1):219-227, 2011

Hribal M.L, Presta I, Procopio T, Marini A.M, Stančáková A, Rutanen J, Hansen T, Zobel D.P, Stefan N, Fritche A, Hammarstedt A, Jansson P-A, Häring H.U, Pedersen O, Smith U, Laakso M, Sesti G, for the EUGENE2 Consortium. Glucose tolerance, insulin sensitivity and insulin release in European non-diabetic carriers of a polymorphism upstream of CDKN2A and CDKN2B. Diabetologia 54:795-802, 2011

Palming J, Jansson PA, Renström F, Johansson A, Johansson L, Karlsson C, Lind L and Eriksson JW: Hydrochlorothiazide compared to candesartan treatment increases adipose tissue gene expression and circulating levels of serum amyloid A in hypertensive patients. Horm Metab Res 43(5):319-324, 2011

Bunck M, Eliasson B, Corner A, Heine R, Shaginian R, Taskinen M-R, Yki-Järvinen H, Smith U and Diamant M. Exenatide treatment did not affect bone mineral density despite body weight reduction in patients with type 2 diabetes. Diabetes Obes Metab 13:374-377, 2011

Svensson MK, Eriksson JW: Change in the amount of body fat and IL-6 levels is related to altered insulin sensitivity in Type 1 diabetes patients with or without diabetic nephropathy. Horm Metab Res 43:209-215, 2011

Jensen J, Ruge T, Lai YC, Svensson MK and Eriksson JW: Effects of adrenaline on whole-body glucose metabolism and insulin-mediated regulation of glycogen synthase and PKB phosphorylation in human skeletal muscle. Metabolism, 60:215-226, 2011

Pfister R, Cairns R, Erdmann E, Schneider CA; PROactive investigators: Prognostic impact of electrocardiographic signs in patients with Type 2 diabetes and cardiovascular disease: results from the PROactive study. Diabet Med 28(10):1206-1212, 2011

Håkansson J, Eliasson B, Smith U and Enerbäck S: Adipocyte mitochondrial genes and the forkhead factor FOXC2 are decreased in type 2 diabetes patients and normalized in response to rosiglitazone. Diabetology & Metabolic Syndrome 3:32, 2011


Nerstedt A, Johansson A, Andersson C.X, Cansby E, Smith U and Mahlapuu M: AMP-activated protein kinase inhibits IL-6-stimulated inflammatory response in human liver cells by suppressing phosphorylation of signal transducer and activator of transcription 3 (STAT3). Diabetologia 53:2406-2416, 2010

Renehan A.G, Smith U and Kirkman S: Linking diabetes and cancer: a consensus on its complexity. Lancet 375(9733):2201-2202, 2010

Smith U and Gale E.A.M: Cancer and diabetes – Are we ready for prime time? Diabetologia 53:1541-1544, 2010

Bunck M, Cornér A, Eliasson B, Heine, R.J, Shaginian R.M, Wu Y, Yan P, Smith U, Yki-Järvinen H, Diamant M, Taskinen M-R. One-year treatment with exenatide vs. insulin glargine: effects on postprandial glycemia, lipid profiles, and oxidative stress. Atherosclerosis 212:223-229, 2010

Bunck M, Diamant M, Eliasson B, Cornér A, Shaginian R.M, Heine R.J, Taskinen M-R, Yki-Järvinen H and Smith U: Exenatide affected circulating cardiovascular risk biomarkers independently of changes in body composition. Diabetes Care 33:1734-1737, 2010

Gustafson B and Smith U: Activation of canonical Wingless-type MMTV integration site family (WNT) signaling in mature adipocytes increases beta-catenin levels and leads to cell dedifferentiation and insulin resistance. J Biol Chem 285:14031-14041, 2010

Wallerstedt E, Smith U and Andersson C.X: Protein kinase C-δ is involved in the inflammatory effect of IL-6 in mouse adipose cells. Diabetologia 53:946-954, 2010

Gustafson B, Eliasson B and Smith U: Thiazolidinediones increase the wingless-type MMTV integration site family (WNT) inhibitor Dickkopf-1 in adipocytes: a link with osteogenesis. Diabetologia 53:536-540, 2010

Smith U & Hammarstedt A: Antagonistic effects of thiazolidinediones and cytokines in lipotoxicity. BBA – Molecular and Cell Biology of Lipids 1801:377-380, 2010

Handberg A, Norberg M, Stenlund H, Attermann J and Eriksson JW: Soluble CD36 clusters with markers of insulin resistance, and high sCD36 is associated with increased type 2 diabetes risk. J Clin Endocrinol Metab 95:1939-1946, 2010


Murdolo G, Hammarstedt A, Schmeiz M, Jansson PA and Smith U: Acute Hyperinsulinemia Differentially Regulates Interstitial and Circulating Adiponectin Oligomeric Pattern in Lean and Insulin-Resistant, Obese Individuals. J Clin Endocrinol Metab 94:4508-4516, 2009

Nauck M, Smith U: Incretin-based therapy: how do incretin mimetics and DPP-4 inhibitors fit into treatment algorithms for type 2 diabetic patients? Best Pract Res Clin Endocrinol Metab 23(4):513-523, 2009

Boesgaard TW, Gjesing AP, Rutanen J, Jansson P-A, Hribal ML, Sesti G, Fritsche A, Stefan N, Häring H, Smith U, Laakso M, Pedersen O, Hansen T, for the EUGENE2 Consortium. Variation near ADAMTS9 known to associate with type 2 diabetes is related to insulin resistance in offspring of type 2 diabetes patients – EUGENE2 study. PloS One 4(9):e7236, 2009

Gogg S, Smith U and Jansson P-A: Increased MAPK activation and impaired insulin signaling in subcutaneous microvascular endothelial cells in Type 2 diabetes – role of endothelin-1. Diabetes 58:2238-2245, 2009

Gustafson B, Gogg S, Hedjazifar S, Jenndahl, L, Hammarstedt A and Smith U: Inflammation and impaired adipogenesis in hypertrophic obesity in man. Am J Physiol Endocrinol Metab 297:E999-E1003, 2009

Koutnikova H, Laakso M, Lu L, Combe R, Paananen J, Kuulasmaa T, Kuusisto J, Häring H, Hansen T, Pedersen O, Smith U, Hanefeld M, Williams R.W and Auwerx J: Identification of the UBP1 locus as a critical blood pressure determinant using a combination of mouse and human genetics. PLoS Genet 5(8): e1000591, 2009

Smith U and Gale E. Does diabetes therapy influence the risk of cancer? Diabetologia 52:1699-1708, 2009

Isakson P, Hammarstedt A, Gustafson B and Smith U: Impaired preadipocytes differentiation in human abdominal obesity – role of Wnt, TNFalpha and inflammation. Diabetes 58:1550-1557, 2009

Bunck M.C, Diamant M, Corner A, Eliasson B, Malloy J.L, Shaginian R.M, Deng W, Kendall D.M, Taskinen M-R, Smith U, Yki-Järvinen H and Heine R.J: One-year treatment with exenatide improves beta-cell function, compared with insulin glargine in metformin treated type 2 diabetic patients: a randomized, controlled trial. Diabetes Care 32:762-768, 2009

Kindblom JM, Ohlsson C, Ljunggren O, Karlsson MK, Tivesten A, Smith U and Mellström D: Plasma osteocalcin is inversely related to fat mass and plasma glucose in elderly Swedish men. J Bone Miner Res 24(5):785-791, 2009

Ruge T, Lockton A, Renstrom F, Lundgren M, Lystig T, Sukonina V, Svensson MK and Eriksson JW: Hyperinsulinaemia can acutely increase plasma IL-6 and TNFα levels – modulation by adiposity but not insulin resistance. Metabolism 58:860-866, 2009

Eriksson JW and Jansson PA: The Response to: Distinct metabolic effects of different classes of antihypertensive drugs. Letter. Hypertension 53:e27, 2009

Newcomer JW, Ratner RE, Eriksson JW, Emsley R, Meulien D, Miller F, Risberg S, Leonova-Edlund J, Leong R and Brecher M: A 24-week, multicenter, open-label, randomized study to compare the effects of olanzapine, quetiapine and risperidone on glucose metabolism in patients with schizophrenia. J Clin Psychiatry 70:487-499, 2009

Pereira MJ, Carvalho E, Eriksson JW, Crans DC and Aureliano M: Effects of decavanadate and insulin mimetic vanadium compounds on glucose uptake in isolated rat adipocytes. J Inorg Biochem 103:1687-1692, 2009

Renström F, Burén J, Svensson M and Eriksson JW: Factors in serum from type 2 diabetes patients can cause cellular insulin resistance. Horm Metab Res 41:767-772, 2009

Sjöholm K, Lundgren M, Olsson M and Eriksson JW: Association of serum amyloid A levels with adipocyte size and serum levels of adipokines: Differences between men and women. Cytokine 48:260-266, 2009

Sjöstrand M and Eriksson JW: Neuroendocrine mechanisms in insulin resistance. Mol Cell Endocrinol 297:104-111, 2009


Friedrich B, Weyrich P, Stančáková A, Wang J, Kuusisto J, Laakso M, Sesti G, Succurro E, Smith U, Hansen T, Pedersen O, Machicao F, Schäfer S, Lang F, Risler T, Ullrich S, Stefan N, Fritsche A and Häring H-U. Variance of the SGK1 gene is associated with insulin secretion in different European populations: results from the TUEF, EUGENE2 and METSIM studies. PLoS ONE 3 (11):e3506, 2008

Halban P.A and Smith U. Order! Order! Order in the House! DIAMAP: a road map for European diabetes research. Diabetologia 51:1765-1767, 2008

Hammarsten J, Damber J-E, Karlsson M, Knutson T, Ljunggren Ö, Ohlsson C, Peeker R, Smith U and Mellström D. Insulin and free oestradiol are independent risk factors for benign prostatic hyperplasia. Prostate Cancer Prostatic Dis. 2008 doi:10.1038/pcan.2008.50

Gustafson B and Smith U: WNT signalling is both an inducer and effector of glucagon-like peptide-1. Diabetologia 51:1768-1770, 2008

Andersson C.X, Gustafson B, Hammarstedt A, Hedjazifar S and Smith U. Inflamed adipose tissue, insulin resistance and vascular injury. Diabetes/Metab Res Rev 24:595-603, 2008

Franckhauser S, Elias I, Rotter Sopasakis V, Ferré T, Nagaev I, Andersson C.X, Agudo J, Ruberte J, Bosch F and Smith U. Overexpression of IL-6 leads to hyperinsulinemia, liver inflammation and reduced body weight. Diabetologia 51:1306-1316, 2008

Boesgaard T.W, Zilinskaitè J, Vänttinen M, Laakso M, Jansson P-A, Hammarstedt A, Smith U, Stefan N, Fritsche A, Häring H, Hribal M, Sesti G, Packert Jensen D, Pedersen O, Hansen T for the EUGENE2 Consortium. The common SLC30A8 Arg325Trp variant is associated with reduced first phase insulin release in 846 non-diabetic offspring of type 2 diabetes patients – the EUGENE2 study. Diabetologia 51: 816-820, 2008

Stancáková A, Pihlajamäki J, Kuusisto J, Stefan N, Fritsche A, Häring H, Andreozzi F, Succurro E, Sesti G, Welløv Boesgaard T, Hansen T, Pedersen O, Jansson P-A, Hammarstedt A, Smith U, Laakso M for the EUGENE2 Consortium. SNP rs7754840 of CDKAL1 is associated with impaired insulin secretion in non-diabetic offspring of Type 2 diabetic subjects (the EUGENE2 study) and in a large sample of men with normal glucose tolerance. J Clin Endocrinol Metab, doi:10.1210/jc.2007-2218, 2008

Hammarstedt A, Pihlajamäki J, Graham T, Kainulainen S, Kahn BB, Laakso M and Smith U: High circulating levels of RBP4 and mRNA levels of aP2, PGC-1 and UCP-2 predict improvement in insulin sensitivity following pioglitazone treatment of drug-naïve type 2 diabetic subjects. J Int Med 263:440-449, 2008

Andersson CX, Hammarstedt A, Jansson P-A and Smith U: Insulin signaling in Adipocytes and the Role of Inflammation. In the Metabolic Syndrome; Epidemiology, Clinical Treatment, and Underlying Mechanisms. Edited by B.C. Hansen and G.A. Bray. Humana Press 2008

Staiger H, Stancáková A, Zilinskaite J, Vänttinen M, Hansen T, Adelaide Marini M, Hammarstedt A, Jansson P-A, Sesti G, Smith U, Pedersen O, Laakso M, Stefan N, Fritsche A and Häring H: A candidate type 2 diabetes polymorphism near the HHEX locus affects acute glucose-stimulated insulin release in European populations: results from the EUGENE2 study. Diabetes 57:514-517, 2008

Laakso M, Zilinskaite J, Hansen T, Welløv Boesgaard T, Vänttinen M, Stancáková A, Jansson P-A, Pellmé F, Holst J.J, Kuulasmaa T, Hribal M.L, Sesti G, Stefan N, Fritsche A, Häring H, Pedersen O and Smith U for the EUGENE2 Consortium: Insulin sensitivity, insulin release and glucagon-like peptide-1 levels in persons with impaired fasting glucose and/or impaired glucose tolerance in the EUGENE2 study. Diabetologia 51:502-511, 2008

Krachler B, Norberg M , Eriksson JW, Hallmans G, Johansson I, Vessby B, Weinehall L and Lindahl B: Fatty acid profile of the erythrocyte membrane preceding development of Type 2 diabetes mellitus. Nutr Metab Cardiovasc Dis, 18:503-510, 2008

Möllsten A, Kockum I, Svensson M, Rudberg S, Ugarph-Morawski A, Brismar K, Eriksson JW and Dahlquist G: The effect of polymorphisms in the renin-angiotensin-aldosterone system on diabetic nephropathy risk. J Diab Complic 22:377-383, 2008

Östman J, Lönnberg G, Arnqvist HJ, Blohmé G, Bolinder J, Ekbom-Schnell A, Eriksson JW, Gudbjörnsdottir S, Sundkvist G and Nyström L: Gender differences and temporal variation in the incidence of type 1 diabetes: results of 8012 cases in the nationwide Diabetes Incidence Study in Sweden 1983–2002. J Intern Med 263:386-394, 2008

Califf RM, Boolell M, Haffner SM, Bethel MA, McMurray J, Duggal A, Holman RR and NAVIGATOR Study Group (incl Eriksson JW): Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial. Am Heart J. 156:623-32, 2008

Wang Z-H, Kihl-Selstam E and Eriksson JW: Ketoacidosis occurs in both type 1 and type 2 diabetes - a population-based study from Northern Sweden. Diabet Med 25:867-870, 2008

Burén J, Lai YC, Lundgren M, Eriksson JW and Jensen J: Insulin action and signalling in fat and muscle from dexamethasone-treated rats. Arch Biochem Biophys 474:91-101, 2008

Bakhtadze E , Cervin C, Lindholm E, Borg H., Nilsson P, Arnqvist H. J., Bolinder J, Eriksson JW, Gudbjörnsdottir S, Nyström L, Agardh C-D, Landin-Olsson M, Sundkvist G and Groop LC: Common variants in the TCF7L2 gene discriminate between autoimmune and non-autoimmune diabetes in young (15-34 years) but not in middle-aged (40-59 years) diabetic patients. Diabetologia 51:2224-2232, 2008

Lundgren M, Burén J, Lindgren P, Myrnäs T, Ruge T and Eriksson JW: Sex differences in depot-specific lipolysis regulation in human adipocytes - interplay between adrenergic stimulation, glucocorticoids and insulin. Horm Metab Res 40:854-860, 2008

Eriksson JW, Jansson PA, Carlberg B, Hägg A, Kurland L, Lönn L, Svensson M, Ström C, Öjbrandt K, Johansson L and Lind L: Hydrochlorothiazide, but not candesartan, aggravates insulin resistance and causes visceral and hepatic fat accumulation. The MEDICA study. Hypertension 52:1030-1037, 2008


Vandenput L, Mellström D, Lorentzon M, Swanson C, Karlsson MK, Brandberg J, Lönn L, Orwoll E, Smith U, Labrie F, Ljunggren Ö, Tivesten Å and Ohlsson C: Androgens and glucuronidated androgen metabolites are associated with metabolic risk factors in men. J Clin Endocrinol Metab 92:4130-4137, 2007

Swanson C, Mellström D, Lorentzon M, Vandenput L, Jakobsson J, Rane A, Karlsson M, Ljunggren Ö, Smith U, Eriksson A-L, Bélanger A, Labrie F and Ohlsson C: The uridine diphosphate glucuronosyltransferase 2B15 D85Y and 2B17 deletion polymorphisms predict the glucuronidation pattern of androgens and fat mass in men. J Clin Endocrinol Metab 92:4878-4882, 2007

Gustafson B, Hammarstedt A, Andersson C.X, and Smith U: Inflamed adipose tissue, a culprit underlying the Metabolic Syndrome and Atherosclerosis. Arterioscler Thromb Vasc Biol 27:2276-2283, 2007

Pirinen E, Kuulasmaa T, Pietilä M et al. Reduced Fat mass, Improved Glucose Tolerance and Enhanced Expression of PGC-1alpha and AMPK in White Adipose Tissue of Transgenic Mice with Activated Polyamine Catabolism. Mol Cell Biol 27:4953, 2007

Hammarstedt A, Isakson P, Gustafson B, Smith U: Wnt-signaling is maintained and adipogenesis inhibited by TNFalpha but not MCP-1 and resistin. Biochem Biophys Res Commun 357:700-706, 2007

Yang X & Smith U: Adipose tissue distribution and risk of metabolic disease: does thiazolidinedione-induced adipose tissue redistribution provide a clue to the answer? Diabetologia 50:1127-1139, 2007

Smith U: TCF7L2 and type 2 diabetes – we WNT to know. Diabetologia 50:5-7, 2007

Andersson C.X, Rotter Sopasakis V, Wallerstedt E and Smith U: Insulin antagonizes IL-6 signaling and is anti-inflammatory in 3T3-L1 adipocytes. J Biol Chem 282:9430-9435, 2007

Eeg-Olofsson K, Cederholm J, Nilsson PM, Gudbjornsdottir S, Eliasson B; Steering Committee of the Swedish National Diabetes Register. Glycemic and risk factor control in type 1 diabetes: results from 13,612 patients in a national diabetes register. Diabetes Care 30:496-502, 2007

Eliasson B, Gudbjörnsdottir S, Cederholm J, Yiang L, Vercruysse F and Smith U: Weight loss and metabolic effects of topiramate in overweight and obese type 2 diabetic patients: randomized double-blind placebo-controlled trial. Int J Obes 31:1140-1147, 2007

Torffvit O, Eriksson JW, Sundkvist G, Arnqvist HJ, Bjork E, Blohme G, Bolinder J, Henricsson M, Nystrom L, Ostman J and Svensson M: Early changes in glomerular size selectivity in young adults with type 1 diabetes and retinopathy Results from the Diabetes Incidence Study in Sweden – DISS. J Diab Complic 21:246-251, 2007

Norberg M, Stenlund H, Andersson C, Lindahl B, Weinehall L, Hallmans G and Eriksson JW: Clusters of components of the metabolic syndrome and adipose-derived mediators in the prediction of future type 2 diabetes - no independent role of inflammation or dyslipidemia. Obesity 15:1875-1885, 2007

Norberg M, Andersson C, Eriksson JW, Lindahl B, Stenlund H and Weinehall L: Work stress and low emotional support is associated with increased risk of future type 2 diabetes in women. Diab Res Clin Pract 76:368-377, 2007

Kalani M, Apelqvist J, Blombäck M, Eliasson B, Eriksson JW, Fagrell B, Hamsten A, Torffvit O, Jörneskog G: Microvascular function following dalteparin treatment of diabetes patients with chronic foot ulcers. Thromb Res 120:653-661, 2007

Eriksson A, Attvall S, Bonnier M, Eriksson JW, Rosander B and Karlsson FA: Short-term effects of metformin in type 2 diabetes – evidence for involvement of adipose tissue. Diab Obes Metab 9:330-336, 2007

Lundgren M, Svensson M, Lindmark S, Renström F, Ruge T and Eriksson JW: Fat cell enlargement is an independent marker of insulin resistance and “hyperleptinaemia”. Diabetologia 50:625-633, 2007

Burén J, Renström F, Svensson M and Eriksson JW: Insulin resistance induced by high glucose and high insulin precedes insulin receptor substrate 1 protein depletion in human adipocytes. Metabolism 56:190-198, 2007

Murdolo G, Hammarstedt A, Sandqvist M, Schmelz M, Herder C, Smith U and Jansson P-A: Monocyte chemoattractant protein-1 (MCP-1) in subcutaneous abdominal adipose tissue: characterization of interstitial concentration and regulation of gene expression by insulin. J Clin Endocrin Metab 92:2688-2695, 2007.

The laboratory has published more than 500 articles in national and international journals

Page Manager: Gunilla Lindell|Last update: 8/23/2017

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?